Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver?


Journal

European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661

Informations de publication

Date de publication:
15 Sep 2020
Historique:
received: 06 05 2020
accepted: 26 05 2020
pubmed: 15 6 2020
medline: 21 8 2020
entrez: 15 6 2020
Statut: ppublish

Résumé

Telehealth services are rapidly embraced in uro-oncology due to the current coronavirus disease 2019 (COVID-19) pandemic. To determine patients' perspective on adoption of telehealth as a response to the pandemic and its sustainability in the future. Following a COVID-19 outbreak, 101 patients with advanced genitourinary cancers are currently managed "virtually" for therapy administration at our tertiary care unit. They were surveyed about the current situation, and current and long-term employment of telehealth. Rapid implementation of virtual patient management. Patients' perception of anxiety of COVID-19 and cancer, perspective on telehealth measures as a reaction to the current COVID-19 pandemic, and long-term acceptance were used as outcomes. Wilcoxon matched-pair signed rank test, chi-square test, and Mann-Whitney U test were performed. Of 101 patients, 92 answered the questionnaire, with 71 (77.2%) responding virtually by e-mail or phone call. Anxiety of cancer (6/10, interquartile range [IQR] 3-8) superseded that of COVID-19 (four/10, IQR 2-5.25, p<0.001), and patients oppose temporary treatment interruption. Of the patients, 66.0% perceive their susceptibility to COVID-19 as equal to or lower than the general population and 52.2% believe that COVID-19 will not affect their therapy. In future, patients (62.6%) prefer to maintain in-person appointments as opposed to complete remote care, but accept remote care during the pandemic (eight/10, IQR 5-9). Beyond the crisis, maintaining telehealth has low preference rates (four/10, IQR 2-7), with high acceptance for external laboratory controls (60.9%) and online visit management (48.9%), but lower acceptance for remote treatment planning including staging discussions (44.6%) and for referral to secondary care oncologists (17.4%). Despite the pandemic, cancer remains the key concern and patients are not willing to compromise on their treatment. Rapid implementation of telehealth is tolerated well during the need of social distancing, with a clear "red line" concerning changes in existing patient-physician relationships. Balancing future implementation of telehealth while considering patients' demand for personal relationships will ensure human dignity in uro-oncology. We queried patients with genitourinary cancers treated in an almost virtual setting following a local coronavirus outbreak. Acceptance of telehealth during the current situation is high; however, long-term implementation of the adapted services is less favored. We deduce that patient-physician relationship is crucial for cancer patients and needs to be balanced against measures for social distancing to forge the future management.

Sections du résumé

BACKGROUND BACKGROUND
Telehealth services are rapidly embraced in uro-oncology due to the current coronavirus disease 2019 (COVID-19) pandemic.
OBJECTIVE OBJECTIVE
To determine patients' perspective on adoption of telehealth as a response to the pandemic and its sustainability in the future.
DESIGN, SETTING, AND PARTICIPANTS METHODS
Following a COVID-19 outbreak, 101 patients with advanced genitourinary cancers are currently managed "virtually" for therapy administration at our tertiary care unit. They were surveyed about the current situation, and current and long-term employment of telehealth.
INTERVENTION METHODS
Rapid implementation of virtual patient management.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS METHODS
Patients' perception of anxiety of COVID-19 and cancer, perspective on telehealth measures as a reaction to the current COVID-19 pandemic, and long-term acceptance were used as outcomes. Wilcoxon matched-pair signed rank test, chi-square test, and Mann-Whitney U test were performed.
RESULTS AND LIMITATIONS CONCLUSIONS
Of 101 patients, 92 answered the questionnaire, with 71 (77.2%) responding virtually by e-mail or phone call. Anxiety of cancer (6/10, interquartile range [IQR] 3-8) superseded that of COVID-19 (four/10, IQR 2-5.25, p<0.001), and patients oppose temporary treatment interruption. Of the patients, 66.0% perceive their susceptibility to COVID-19 as equal to or lower than the general population and 52.2% believe that COVID-19 will not affect their therapy. In future, patients (62.6%) prefer to maintain in-person appointments as opposed to complete remote care, but accept remote care during the pandemic (eight/10, IQR 5-9). Beyond the crisis, maintaining telehealth has low preference rates (four/10, IQR 2-7), with high acceptance for external laboratory controls (60.9%) and online visit management (48.9%), but lower acceptance for remote treatment planning including staging discussions (44.6%) and for referral to secondary care oncologists (17.4%).
CONCLUSIONS CONCLUSIONS
Despite the pandemic, cancer remains the key concern and patients are not willing to compromise on their treatment. Rapid implementation of telehealth is tolerated well during the need of social distancing, with a clear "red line" concerning changes in existing patient-physician relationships. Balancing future implementation of telehealth while considering patients' demand for personal relationships will ensure human dignity in uro-oncology.
PATIENT SUMMARY RESULTS
We queried patients with genitourinary cancers treated in an almost virtual setting following a local coronavirus outbreak. Acceptance of telehealth during the current situation is high; however, long-term implementation of the adapted services is less favored. We deduce that patient-physician relationship is crucial for cancer patients and needs to be balanced against measures for social distancing to forge the future management.

Identifiants

pubmed: 32534969
pii: S2405-4569(20)30145-0
doi: 10.1016/j.euf.2020.05.010
pmc: PMC7286644
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1097-1103

Informations de copyright

Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Références

Clin Genitourin Cancer. 2021 Feb;19(1):76-82.e6
pubmed: 32527682
J Telemed Telecare. 2018 Jan;24(1):4-12
pubmed: 29320966
Eur Urol. 2020 Jun;77(6):667-668
pubmed: 32312544
Lancet. 2020 Apr 25;395(10233):1382-1393
pubmed: 32277878
N Engl J Med. 2020 Apr 30;382(18):1677-1679
pubmed: 32109012
N Engl J Med. 2020 Jun 11;382(24):2285-2287
pubmed: 32267650
N Engl J Med. 2020 Apr 30;382(18):1679-1681
pubmed: 32160451
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
JAMA. 2017 Jul 11;318(2):197-198
pubmed: 28586821
Psychol Sci. 2015 Feb;26(2):135-47
pubmed: 25526910
Eur J Cancer. 2020 Jun;132:136-140
pubmed: 32361628
NPJ Digit Med. 2019 Jun 14;2:53
pubmed: 31304399
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
AMIA Annu Symp Proc. 2015 Nov 05;2015:543-52
pubmed: 26958188
Eur J Cancer. 2020 Jun;132:17-23
pubmed: 32311643
N Engl J Med. 2020 Jun 4;382(23):e82
pubmed: 32240581
Clin Transl Oncol. 2018 Nov;20(11):1392-1399
pubmed: 29611043
N Engl J Med. 2020 Jun 11;382(24):2368-2371
pubmed: 32302076
N Engl J Med. 2020 Aug 6;383(6):510-512
pubmed: 32283003

Auteurs

Severin Rodler (S)

Klinik und Poliklinik für Urologie, Klinikum der Universität München, Munich, Germany; Comprehensive Cancer Center, Klinikum der Universität München, Munich, Germany. Electronic address: severin.rodler@med.uni-muenchen.de.

Maria Apfelbeck (M)

Klinik und Poliklinik für Urologie, Klinikum der Universität München, Munich, Germany; Comprehensive Cancer Center, Klinikum der Universität München, Munich, Germany.

Gerald Bastian Schulz (GB)

Klinik und Poliklinik für Urologie, Klinikum der Universität München, Munich, Germany.

Troya Ivanova (T)

Klinik und Poliklinik für Urologie, Klinikum der Universität München, Munich, Germany.

Alexander Buchner (A)

Klinik und Poliklinik für Urologie, Klinikum der Universität München, Munich, Germany.

Michael Staehler (M)

Klinik und Poliklinik für Urologie, Klinikum der Universität München, Munich, Germany.

Volker Heinemann (V)

Comprehensive Cancer Center, Klinikum der Universität München, Munich, Germany; Medizinische Klinik III, Klinikum der Universität München, Munich, Germany.

Christian Stief (C)

Klinik und Poliklinik für Urologie, Klinikum der Universität München, Munich, Germany.

Jozefina Casuscelli (J)

Klinik und Poliklinik für Urologie, Klinikum der Universität München, Munich, Germany; Comprehensive Cancer Center, Klinikum der Universität München, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH